Molecule Holdings Stock Fundamentals
EVRRF Stock | USD 0 0.00 0.00% |
Molecule Holdings fundamentals help investors to digest information that contributes to Molecule Holdings' financial success or failures. It also enables traders to predict the movement of Molecule Pink Sheet. The fundamental analysis module provides a way to measure Molecule Holdings' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Molecule Holdings pink sheet.
Molecule |
Molecule Holdings Company Operating Margin Analysis
Molecule Holdings' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Molecule Holdings Operating Margin | (2.15) % |
Most of Molecule Holdings' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Molecule Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Competition |
Based on the recorded statements, Molecule Holdings has an Operating Margin of -2.1462%. This is 93.88% lower than that of the Metals & Mining sector and significantly lower than that of the Materials industry. The operating margin for all United States stocks is 61.05% lower than that of the firm.
Molecule Holdings Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Molecule Holdings's current stock value. Our valuation model uses many indicators to compare Molecule Holdings value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Molecule Holdings competition to find correlations between indicators driving Molecule Holdings's intrinsic value. More Info.Molecule Holdings is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Molecule Holdings' earnings, one of the primary drivers of an investment's value.Molecule Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Molecule Holdings' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Molecule Holdings could also be used in its relative valuation, which is a method of valuing Molecule Holdings by comparing valuation metrics of similar companies.Molecule Holdings is currently under evaluation in operating margin category among its peers.
Molecule Fundamentals
Return On Equity | -10.88 | |||
Return On Asset | -0.41 | |||
Profit Margin | (2.43) % | |||
Operating Margin | (2.15) % | |||
Current Valuation | 5.39 M | |||
Shares Outstanding | 97.78 M | |||
Shares Owned By Insiders | 16.52 % | |||
Price To Earning | (2.27) X | |||
Price To Book | 12.35 X | |||
Price To Sales | 0.0001 X | |||
Revenue | 455.26 K | |||
Gross Profit | (499.74 K) | |||
EBITDA | (3 M) | |||
Net Income | (4.23 M) | |||
Cash And Equivalents | 73.25 K | |||
Total Debt | 817.09 K | |||
Debt To Equity | 1.37 % | |||
Current Ratio | 0.31 X | |||
Book Value Per Share | (0.02) X | |||
Cash Flow From Operations | (2.87 M) | |||
Earnings Per Share | (0.04) X | |||
Number Of Employees | 15 | |||
Beta | -0.64 | |||
Market Capitalization | 1.45 M | |||
Total Asset | 5.96 M | |||
Retained Earnings | (26.52 M) | |||
Working Capital | 504 K | |||
Current Asset | 1.13 M | |||
Current Liabilities | 622 K | |||
Z Score | -5.0 | |||
Net Asset | 5.96 M |
About Molecule Holdings Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Molecule Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Molecule Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Molecule Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Molecule Holdings Inc. engages in production and co-packing of cannabis-infused beverages in Canada. It offers its beverage products under the PHRESH, embody, and CANAJO brands. Molecule Holdings is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Molecule Pink Sheet
Molecule Holdings financial ratios help investors to determine whether Molecule Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Molecule with respect to the benefits of owning Molecule Holdings security.